Sector News

Regeneron tops best science employer poll again

October 17, 2014
Life sciences
Regeneron has once again come top of Science magazine’s top 20 employers survey, followed by Novo Nordisk and Roche’s Genentech unit.
 
The poll is based on 5,394 responses from readers of Science and employees in the biotechnology and pharmaceutical industry, who were asked to rank the best employers on a number of characteristics. The categories included ‘’innovative leader in the industry’, treats employees with respect’, ‘has loyal employees’ and ‘is socially responsible’.
 
Regeneron came out as the top company for the third year in a row, while Novo leapt to second from 11th place last year. They were followed by Genentech, Vertex (4), Eli Lilly (5), AbbVie (7) and Roche itself, up eight places from last year to eighth.
 
Biogen Idec came in at 10th, while Novartis slipped three places to 11th. Newcomers to the list were Actelion (14), Johnson & Johnson (19) and Merck KGaA (20). The other pharma players in the top 20 are Boehringer Ingelheim (13, down from 9), Celgene (up two places to 15), Bayer (up four to 16) and Amgen, which rose one place to 18th.
 
Science claims that “a common thread runs through the top 20 list: give employees the intellectual freedom and support necessary to pursue high-risk/high-reward goals – and they’ll deliver”. The journal says that by adding “a noble mission” to this, “employers can create a positive feedback loop that maximises employees’ drive and dedication as well as company profits”.
 
By Kevin Grogan
 

comments closed

Related News

October 17, 2021

Colorcon acquires a majority share in Ideal Cures Pvt. Ltd., India

Life sciences

Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.

October 17, 2021

Barriers exist, but participation urgent in breast cancer clinical trials: report

Life sciences

Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.

October 17, 2021

Danish consortium acquires part of Jernbanebyen to create one of the world’s healthiest urban villages

Life sciences

The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world. 

Send this to a friend